[go: up one dir, main page]

WO2001012838A3 - Compounds which modulate the activity of an lpa receptor - Google Patents

Compounds which modulate the activity of an lpa receptor Download PDF

Info

Publication number
WO2001012838A3
WO2001012838A3 PCT/US2000/022101 US0022101W WO0112838A3 WO 2001012838 A3 WO2001012838 A3 WO 2001012838A3 US 0022101 W US0022101 W US 0022101W WO 0112838 A3 WO0112838 A3 WO 0112838A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulate
activity
compounds
lpa receptor
lpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/022101
Other languages
French (fr)
Other versions
WO2001012838A2 (en
Inventor
James Erickson
J Graham Goddard
Michael Kiefer
Donald Picker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atairgin Technologies Inc
Original Assignee
Atairgin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atairgin Technologies Inc filed Critical Atairgin Technologies Inc
Priority to AU70577/00A priority Critical patent/AU7057700A/en
Publication of WO2001012838A2 publication Critical patent/WO2001012838A2/en
Publication of WO2001012838A3 publication Critical patent/WO2001012838A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides novel methods for identifying and characterizing compounds which modulate the activity of an LPA receptor.
PCT/US2000/022101 1999-08-18 2000-08-11 Compounds which modulate the activity of an lpa receptor Ceased WO2001012838A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70577/00A AU7057700A (en) 1999-08-18 2000-08-11 Compounds which modulate the activity of an lpa receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37639999A 1999-08-18 1999-08-18
US09/376,399 1999-08-18

Publications (2)

Publication Number Publication Date
WO2001012838A2 WO2001012838A2 (en) 2001-02-22
WO2001012838A3 true WO2001012838A3 (en) 2001-10-04

Family

ID=23484875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022101 Ceased WO2001012838A2 (en) 1999-08-18 2000-08-11 Compounds which modulate the activity of an lpa receptor

Country Status (2)

Country Link
AU (1) AU7057700A (en)
WO (1) WO2001012838A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836345B2 (en) * 2001-04-13 2011-12-14 きみ子 室伏 Neuronal survival promoter containing cyclic phosphatidic acid derivative
WO2004044580A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human endothelial differentiation, lysophosphatidic acid g-protein-coupled receptor 2 (edg2)
JP5826742B2 (en) 2009-05-07 2015-12-02 ドンコック ファーマシューティカル カンパニー リミテッド Pharmaceutical composition for preventing or treating nerve damage and disease
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5176423A (en) * 1974-12-26 1976-07-02 Kao Corp HIIRYOYOKOKINZAI
US5480877A (en) * 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
EP0747047A1 (en) * 1995-05-17 1996-12-11 LA ROCHE POSAY Laboratoire Pharmaceutique Combination of an antimicrobial compound (e.g. the lipoaminoacid N,n-octanoyl-glycine) and a monoalkylglycerol ether and its use as an antimicrobial agent
WO1998041213A1 (en) * 1997-03-19 1998-09-24 Lxr Biotechnology Inc. Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
WO1999008514A1 (en) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions containing polyethylene glycol and uses thereof
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
WO1999047101A2 (en) * 1998-03-18 1999-09-23 Lxr Biotechnology, Inc. Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5176423A (en) * 1974-12-26 1976-07-02 Kao Corp HIIRYOYOKOKINZAI
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
US5480877A (en) * 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
EP0747047A1 (en) * 1995-05-17 1996-12-11 LA ROCHE POSAY Laboratoire Pharmaceutique Combination of an antimicrobial compound (e.g. the lipoaminoacid N,n-octanoyl-glycine) and a monoalkylglycerol ether and its use as an antimicrobial agent
WO1998041213A1 (en) * 1997-03-19 1998-09-24 Lxr Biotechnology Inc. Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
WO1999008514A1 (en) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions containing polyethylene glycol and uses thereof
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
WO1999047101A2 (en) * 1998-03-18 1999-09-23 Lxr Biotechnology, Inc. Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDO K ET AL: "ANTITUMOR ACTIVITY OF GLYCERYL ETHERS", CANCER RESEARCH,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD,US, vol. 32, January 1972 (1972-01-01), pages 125 - 129, XP000944227, ISSN: 0008-5472 *
BANDOH, K. ET AL: "Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors", FEBS LETT. (2000), 478(1,2), 159-165, XP000990176 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHIZAWA, KAZUNORI ET AL: "Alkoxyalkanol antimicrobial agents", XP002164099, retrieved from STN Database accession no. 85:159409 *
ERICKSON J R ET AL: "EDG-2/VZG-1 COUPLES TO THE YEAST PHEROMONE RESPONSE PATHWAY SELECTIVELY IN RESPONSE TO LYSOPHOSPHATIDIC ACID", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 3, 16 January 1998 (1998-01-16), pages 1506 - 1510, XP000783622, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU7057700A (en) 2001-03-13
WO2001012838A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
AU4677699A (en) Methods for identifying novel multimeric agents that modulate receptors
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
AU4674599A (en) Novel therapeutic agents that modulate enzymatic processes
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
ZA972587B (en) Implant for fixing an osteotomy.
AU1623200A (en) Method for identifying the language of individual words
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
ZA988961B (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.
AU2003265859A1 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
DK0984665T3 (en) Transducer for partially or completely implantable hearing aid
TR200100885T2 (en) 2-Methyl-thieno-benzodiazepine formulation
ZA985026B (en) Method for enhancing the activity of an enzyme.
WO2001059153A3 (en) Method for identifying substances which modulate the activity of hyperpolarisation-activated cation channels
BR9708347A (en) Tetrahidorbeta-carbonyl compounds
AU4158797A (en) Screening assay for the identification of agents which alter expression of pth-rp
AU2001226387A1 (en) Methods of identifying modulators of the fgf receptor
AU6748000A (en) Method for identifying compounds which modulate circadian rhythm
AU6279500A (en) Epothilone compositions
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU2001294895A1 (en) Methods for identifying compounds that modulate biofilm activity
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
ZA988025B (en) Method for enhancing the activity of an enzyme.
WO2001020335A3 (en) Methods for modulating cell proliferation
WO2000036101A3 (en) An atp-binding cassette protein responsible for cytotoxin resistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP